TransCon PTH FDA Approval Status
FDA Approved: No
Brand name: TransCon PTH
Generic name: palopegteriparatide
Company: Ascendis Pharma, Inc.
Treatment for: Hypoparathyroidism
TransCon PTH (palopegteriparatide) is a prodrug of parathyroid hormone (PTH [1-34]) in development for the treatment of adult patients with hypoparathyroidism.
- Hypoparathyroidism is a rare endocrine disorder characterized by deficient or absent parathyroid hormone, a hormone that plays a critical role in controlling calcium, phosphate and calcitriol (active vitamin D) levels in the blood and bone.
- TransCon PTH is a long-acting, once-daily hormone replacement therapy designed to restore physiologic levels of parathyroid hormone to address both the short-term symptoms and long-term complications of hypoparathyroidism.
Development timeline for TransCon PTH
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
